# Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

> **NCT02971761** · PHASE2 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 18 (actual)

## Conditions studied

- Androgen Receptor Positive
- Estrogen Receptor Negative
- HER2/Neu Negative
- Metastatic Triple-Negative Breast Carcinoma
- Progesterone Receptor Negative
- Stage IV Breast Cancer AJCC v6 and v7

## Interventions

- **DRUG:** Enobosarm
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02971761
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-01
- **Primary completion:** 2020-10-28
- **Final completion:** 2022-08-16
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02971761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02971761, "Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT02971761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*